Correlation Between Objective Evaluation Result of Nasal Congestion and Life Quality in Patients with Acute Rhinosinusitis

The role of house dust mite immunotherapy in Indonesian children with chronic rhinosinusitis allergy: A randomized control trial

Background

Chronic rhinosinusitis allergy (CRA) is a disease that is commonly found in children and is mostly caused by allergy to house dust mites (HDM). The use of HDM immunotherapy can be considered in children with allergies.

Objectives

Analyzing the impact of mite immunotherapy on disease burden in Indonesian children with CRA.

Methods

A randomized control trial study was conducted to participants in 2 groups, namely the immunotherapy group (n = 25) and the non-immunotherapy group (n = 25). Participants were given HDM immunotherapy for 14 weeks, which was given once per week. Participants during therapy were evaluated for rhinosinusitis symptoms and measured their immunity status (specific IgE), sleep quality (SDSC), quality of life (SN5), and family coping (F-COPES) pre-post therapy. Statistical analysis used in this study included paired t-test, Wilcoxon test, independent t-test, or Mann Whitney test with p < 0.05.

Results

The value of specific IgE in the immunotherapy group was 4.12 ± 7.75 kU/l (pre-test) and 1.52 ± 2.42 kU/l (post-test; p < 0.001), while in the non-immunotherapy group was 1.47 ± 3.28 kU/l (pre-test) and 1.18 ± 2.81 kU/l (post-test; p = 0.317). The SDSC value in the immunotherapy group was 42.16 ± 2.75 (pre-test) and 30.32 ± 3.22 (post-test; p < 0.001), while in the non-immunotherapy group was 41.92 ± 2.75 (pre-test) and 41.84 ± 2.87 (post-test; p = 0.987). The F-COPES value in the immunotherapy group was 101.56 ± 5.78 (pre-test) and 105.20 ± 4.31 (post-test; p = 0.015), while in the non-immunotherapy group was 100.36 ± 9.63 (pre-test) and 99.96 ± 9.98 (post-test; p = 0.224). The SN-5 value in the immunotherapy group was 30.04 ± 2.78 (pre-test) and 11.00 ± 2.33 (post-test; p < 0.001), while in the non-immunotherapy group was 30.04 ± 2.78 (pre-test) and 30.04 ± 2.78 (post-test; p = 0.767). There was a significant comparison between the immunotherapy group and the non-immunotherapy group on the specific IgE (p = 0.013), SDSC (p < 0.001), and SN-5 (p < 0.001) values. Meanwhile, there was no significant difference in the F-COPES value (p = 0.129).

Conclusions

The administration of HDM immunotherapy can improve the participant's immunity, quality of life, and sleep disorder.

The Relationship of Preseptoplasty and Postseptoplasty Early Period Comfort Level With Nasal Obstruction, Sleep Quality, and Fatigue Severity: A Prospective Study

PURPOSE

The aim of this study was to compare the comfort level, nasal obstruction, sleep quality, and fatigue of patients with septal deviation preseptoplasty and postseptoplasty.

DESIGN

A prospective study conducted on 65 patients diagnosed with septal deviation.

METHODS

The data of the study were collected using an Introductory Information Form, a Short General Comfort Questionnaire, the Pittsburgh Sleep Quality Index, the Fatigue Severity Scale, and the Nasal Obstruction Septoplasty Effectiveness Scale. Linear regression was performed to evaluate the extent of the relationship of predictors affecting the comfort level.

FINDINGS

There was a statistically significant difference between the scores in the preoperative period and postoperative weeks 4 and 12. It was found that patients' use of sleeping medication, nasal obstruction, fatigue, and subjective sleep quality were the primary predictors of comfort levels in the preoperative period. In the postoperative week 4, comfort level predictors were daytime dysfunction and subjective sleep quality. Daytime dysfunction and working conditions were the predictors of comfort level in the postoperative week 12.

CONCLUSIONS

Many physical problems, such as nasal obstruction, fatigue, and sleep disorders were detected in patients before septoplasty. This study revealed the importance of performing septoplasty before sleep quality reaches a pathologic level or requires a sleep medication.